260 related articles for article (PubMed ID: 28870594)
1. Rebound syndrome after teriflunomide cessation in a patient with multiple sclerosis.
Yamout BI; Said M; Hannoun S; Zeineddine M; Massouh J; Khoury SJ
J Neurol Sci; 2017 Sep; 380():79-81. PubMed ID: 28870594
[TBL] [Abstract][Full Text] [Related]
2. "Nail loss after teriflunomide treatment: A new potential adverse event".
Mancinelli L; Amerio P; di Ioia M; Di Tommaso V; De Luca G; Onofrj M; Lugaresi A
Mult Scler Relat Disord; 2017 Nov; 18():170-172. PubMed ID: 29141803
[TBL] [Abstract][Full Text] [Related]
3. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
4. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
Miller AE; Wolinsky JS; Kappos L; Comi G; Freedman MS; Olsson TP; Bauer D; Benamor M; Truffinet P; O'Connor PW;
Lancet Neurol; 2014 Oct; 13(10):977-86. PubMed ID: 25192851
[TBL] [Abstract][Full Text] [Related]
5. Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis.
Chan A; de Seze J; Comabella M
CNS Drugs; 2016 Jan; 30(1):41-51. PubMed ID: 26758290
[TBL] [Abstract][Full Text] [Related]
6. ▼Teriflunomide for multiple sclerosis.
Drug Ther Bull; 2014 Jul; 52(7):81-4. PubMed ID: 25012149
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study.
Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Brette S; Robinson M; Gold R;
Mult Scler Relat Disord; 2017 Oct; 17():107-115. PubMed ID: 29055438
[TBL] [Abstract][Full Text] [Related]
8. PML in a person with multiple sclerosis: Is teriflunomide the felon?
Lorefice L; Fenu G; Gerevini S; Frau J; Coghe G; Barracciu MA; Contu F; Marrosu MG; Cocco E
Neurology; 2018 Jan; 90(2):83-85. PubMed ID: 29212829
[No Abstract] [Full Text] [Related]
9. Teeth loss after teriflunomide treatment: Casual or causal? A short case series.
Vacchiano V; Frattaruolo N; Mancinelli L; Foschi M; Carotenuto A; Scandellari C; Piattelli M; Brescia Morra V; Lugaresi A
Mult Scler Relat Disord; 2018 Aug; 24():120-122. PubMed ID: 29982109
[TBL] [Abstract][Full Text] [Related]
10. Teriflunomide: a novel oral treatment for relapsing multiple sclerosis.
Sartori A; Carle D; Freedman MS
Expert Opin Pharmacother; 2014 May; 15(7):1019-27. PubMed ID: 24742277
[TBL] [Abstract][Full Text] [Related]
11. Teriflunomide for the treatment of relapsing-remitting multiple sclerosis.
Miller AE
Expert Rev Clin Immunol; 2015 Feb; 11(2):181-94. PubMed ID: 25511008
[TBL] [Abstract][Full Text] [Related]
12. Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis.
Gerschenfeld G; Servy A; Valeyrie-Allanore L; de Prost N; Cecchini J
Mult Scler; 2015 Oct; 21(11):1476-7. PubMed ID: 26199352
[TBL] [Abstract][Full Text] [Related]
13. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
Comi G; Freedman MS; Kappos L; Olsson TP; Miller AE; Wolinsky JS; O'Connor PW; Benamor M; Dukovic D; Truffinet P; Leist TP
Mult Scler Relat Disord; 2016 Jan; 5():97-104. PubMed ID: 26856952
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
Braune S; Grimm S; van Hövell P; Freudensprung U; Pellegrini F; Hyde R; Bergmann A;
J Neurol; 2018 Dec; 265(12):2980-2992. PubMed ID: 30327931
[TBL] [Abstract][Full Text] [Related]
15. Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL; Bar-Or A; Cohen JA; Comi G; Correale J; Coyle PK; Cross AH; de Seze J; Leppert D; Montalban X; Selmaj K; Wiendl H; Kerloeguen C; Willi R; Li B; Kakarieka A; Tomic D; Goodyear A; Pingili R; Häring DA; Ramanathan K; Merschhemke M; Kappos L;
N Engl J Med; 2020 Aug; 383(6):546-557. PubMed ID: 32757523
[TBL] [Abstract][Full Text] [Related]
16. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
Guarnera C; Bramanti P; Mazzon E
Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
[TBL] [Abstract][Full Text] [Related]
17. Teriflunomide in multiple sclerosis: an update.
Miller AE
Neurodegener Dis Manag; 2017 Feb; 7(1):9-29. PubMed ID: 27937746
[TBL] [Abstract][Full Text] [Related]
18. Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report.
Camara-Lemarroy CR; Castilló J; Sastre-Garriga J; Tintore M; Montalban X
Mult Scler; 2018 Sep; 24(10):1383-1385. PubMed ID: 29473796
[TBL] [Abstract][Full Text] [Related]
19. Teriflunomide: a review of its use in relapsing multiple sclerosis.
Garnock-Jones KP
CNS Drugs; 2013 Dec; 27(12):1103-23. PubMed ID: 24198223
[TBL] [Abstract][Full Text] [Related]
20. Palmar pustular psoriasis associated with teriflunomide treatment.
Negrotto L; Correale J
Mult Scler Relat Disord; 2019 Jan; 27():400-402. PubMed ID: 30513502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
